Skip to main content

Table 1 Cure rates (CR), extended CRs, egg-reduction rates (ERR), extended ERRs and reinfection data for the four different treatments against T. trichiura infections. Results of baseline and 3 weeks follow-up have been reported elsewhere [13]

From: Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole

Trichuris trichiura

 

Weeks post-treatment

Albendazole – ivermectin (n = 100)

Albendazole – mebendazole (n = 101)

Albendazole – oxantel pamoate (n = 100)

Mebendazole (n = 104)

Children positive before treatment (%)

100 (100)

101 (100)

100 (100)

104 (100)

No. of children cured (CR, 95 % CI)

3 weeks

28 (28.0, 19.5–37.9, p < 0.001)*

9 (8.9, 4.2–16.2, p < 0.001)*

68 (68.0, 57.9–77.0)

8 (7.7, 3.4–14.6, p < 0.001)*

No. of children negative (extended CR, 95 % CI)

18 weeks

20 (20.0, 12.7–29.2, p < 0.001)*

14 (13.9, 7.8–22.2, p < 0.001)*

54 (54.0, 43.7–64.0)

11 (10.6, 5.4–18.1, p < 0.001)*

Geometric mean: EPG

Baseline

489.9

390.0

471.3

467.8

3 weeks

25.0

176.0

3.7

207.8

18 weeks

47.8

128.1

6.6

158.8

ERR (95 % CI)

3 weeks

94.9 (92.3–96.7)

54.9 (38.3–67.7)

99.2 (98.6–99.6)a

55.6 (40.0–68.0)

Extended ERR (95 % CI)

18 weeks

90.2 (85.3–93.6)

67.2 (51.9–77.9)

98.6 (97.8–99.2)a

66.1 (52.0–76.6)

No. of children positive (prevalence, 95 % CI)

Baseline

100 (100, −)

101 (100, −)

100 (100, −)

104 (100, −)

3 weeks

72 (72.0, 62.1–80.5)

92 (91.1, 83.8–95.8)

32 (32.0, 23.0–42.1)

96 (92.3, 85.4–96.6)

18 weeks

80 (80.0, 70.8–87.3)

87 (86.1, 77.8–92.2)

46 (46.0, 36.0–56.3)

93 (89.4, 81.9–94.6)

Reinfections (%, 95 % CI)

18 weeks

15/28 (53.6, 33.9–72.5)

2/9 (22.2, 2.8–60.0)

21/68 (30.9, 20.2–43.6)

4/8 (50.0, 15.7–84.3)

  1. Data are n (%, 95 % CI) unless otherwise indicated. EPG = egg per gram of stool. *Significantly lower CR compared to albendazole-oxantel pamoate (P-values derived from logistic regression)
  2. aSignificantly higher ERR compared to other treatment arms (no overlapping confidence interval assumption)